Literature DB >> 10525373

FIGO stage IIIC endometrial carcinoma with metastases confined to pelvic lymph nodes: analysis of treatment outcomes, prognostic variables, and failure patterns following adjuvant radiation therapy.

G Nelson1, M Randall, G Sutton, D Moore, J Hurteau, K Look.   

Abstract

OBJECTIVES: This study was undertaken to evaluate the prognostic significance of isolated positive pelvic lymph nodes on survival and to analyze other prognostic variables, overall survival, and failure patterns in surgically staged endometrial carcinoma patients with positive pelvic lymph nodes and negative para-aortic lymph nodes following radiation therapy (RT).
METHODS: Between January 1, 1987, and December 31, 1997, 782 women underwent primary treatment for uterine cancer at Indiana University Medical Center. Through a review of the medical records, we identified 58 patients with pathologic stage IIIA, 27 patients with pathologic stage IIIB, and 77 patients with pathologic stage IIIC endometrial carcinoma. Patients with pathologically positive or unsampled para-aortic lymph nodes and patients who received preoperative radiation therapy were excluded, leaving a study group of 17 patients with nodal metastases confined to pelvic lymph nodes. Thirteen patients received adjuvant pelvic RT using AP-PA or four-field technique. A median dose of 5040 cGy was delivered. Four patients received whole abdominal irradiation (WAI) delivering a median dose of 3000 cGy. Two patients received vaginal cuff boosts of 1000 and 3560 cGy to 0.5 cm from the vaginal surface mucosa via Cs-137 brachytherapy. Two patients also received adjuvant chemotherapy (cis-platinum and doxorubicin) and/or hormonal therapy (megestrol acetate). Disease-free and overall survivals were estimated using the Kaplan-Meier method of statistical analysis and prognostic variables were analyzed using the log-rank test.
RESULTS: With a median follow-up of 51 months the actuarial 5-year disease-free survival was 81% and the actuarial 2-year and 5-year overall survival rates were 81 and 72%, respectively. Univariate analysis revealed that positive peritoneal cytology in conjunction with positive pelvic lymph nodes imparts a greater risk of recurrence and decreased overall survival. There were no pelvic and/or upper abdominal failures, but there were recurrences in the para-aortic lymph nodes (two patients) and distantly (two patients).
CONCLUSION: Surgery followed by postoperative pelvic RT is a viable treatment option for pathologically staged stage IIIC endometrial carcinoma with disease confined to the pelvic lymph nodes. Failures in the para-aortic region suggest a possible role for extended-field RT. Patients with positive peritoneal cytology in conjunction with nodal metastasis fared poorly with pelvic RT. Studies evaluating the efficacy of WAI are ongoing. Finally, substages within FIGO stage IIIC are recommended in an effort to better understand and define treatment strategies which might be appropriate for these patients. Copyright 1999 Academic Press.

Entities:  

Mesh:

Year:  1999        PMID: 10525373     DOI: 10.1006/gyno.1999.5569

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  15 in total

1.  Concomitant postoperative radiation and chemotherapy following surgery was associated with improved overall survival in patients with FIGO stages III and IV endometrial cancer.

Authors:  Kentaro Nakayama; Yutaka Nagai; Masako Ishikawa; Yoichi Aoki; Khoji Miyazaki
Journal:  Int J Clin Oncol       Date:  2010-04-24       Impact factor: 3.402

2.  Combined chemotherapy and radiation improves survival for node-positive endometrial cancer.

Authors:  Larissa J Lee; Akila N Viswanathan
Journal:  Gynecol Oncol       Date:  2012-06-24       Impact factor: 5.482

3.  Adjuvant carboplatin, paclitaxel, and vaginal cuff brachytherapy for stage III endometrial cancer: analysis of outcomes and patterns of recurrence based on pathologic characteristics.

Authors:  Melissa Rasar Young; Susan A Higgins; Elena Ratner; James B Yu; Sheida Mani; Dan-Arin Silasi; Masoud Azodi; Thomas Rutherford; Peter E Schwartz; Shari Damast
Journal:  Int J Gynecol Cancer       Date:  2015-03       Impact factor: 3.437

4.  Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer.

Authors:  Daniela Matei; Virginia Filiaci; Marcus E Randall; David Mutch; Margaret M Steinhoff; Paul A DiSilvestro; Katherine M Moxley; Yong M Kim; Matthew A Powell; David M O'Malley; Nick M Spirtos; William Small; Krishnansu S Tewari; William E Richards; John Nakayama; Ursula A Matulonis; Helen Q Huang; David S Miller
Journal:  N Engl J Med       Date:  2019-06-13       Impact factor: 91.245

5.  Comparison of FIGO 1988 and 2009 staging systems for endometrial carcinoma.

Authors:  Melis Gultekin; Ferah Yildiz; Gokhan Ozyigit; Havva Beyaz; Mutlu Hayran; Faruk Kose; Kunter Yuce; Ali Ayhan
Journal:  Med Oncol       Date:  2012-03-14       Impact factor: 3.064

Review 6.  Endometrial cancer: the management of high-risk disease.

Authors:  Gunnar Kristensen; Claes Tropé
Journal:  Curr Oncol Rep       Date:  2004-11       Impact factor: 5.075

7.  Efficacy of contemporary chemotherapy in stage IIIC endometrial cancer: a histologic dichotomy.

Authors:  Jamie N Bakkum-Gamez; Andrea Mariani; Sean C Dowdy; Amy L Weaver; Michaela E McGree; Janice R Martin; Gary L Keeney; Aminah Jatoi; Bobbie S Gostout; Karl C Podratz
Journal:  Gynecol Oncol       Date:  2014-01-14       Impact factor: 5.482

8.  A phase I study of IV doxorubicin plus intraperitoneal (IP) paclitaxel and IV or IP cisplatin in endometrial cancer patients at high risk for peritoneal failure (GOG 9920): an NRG Oncology/Gynecologic Oncology Group study.

Authors:  D Scott McMeekin; Michael W Sill; Joan L Walker; Kathleen N Moore; Steven E Waggoner; Premal H Thaker; Tina Rizack; James S Hoffman; Paula M Fracasso
Journal:  Gynecol Oncol       Date:  2015-05-06       Impact factor: 5.482

9.  Controversies in the management of endometrial carcinoma: an update.

Authors:  Mohamed K Mehasseb; John A Latimer
Journal:  Obstet Gynecol Int       Date:  2012-02-16

Review 10.  Endometrial cancer: treatment of nodal metastases.

Authors:  D Scott McMeekin; Todd Tillmanns
Journal:  Curr Treat Options Oncol       Date:  2003-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.